To read the full story, subscribe or sign in.

Daiichi Sankyo wins approval in Japan for first oncolytic virus therapy treating malignant glioma

June 16, 2021

Daiichi Sankyo Co. Ltd. has received conditional approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for its oncolytic virus Delytact (teserpaturev) to treat malignant glioma.

BioWorld Regulatory Cancer Japan MHLW

Today's news in brief

BioWorld

BioWorld briefs for Dec. 3, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 3, 2024.

Illustration of man holding magnifying glass to human body model showing muscle anatomy

In muscular dystrophies, gene therapies race the clock

BioWorld

Since the isolation of the gene that causes Duchenne muscular dystrophy (DMD), scientists have progressed in understanding the mechanisms that lead to muscular...

AI-generated illustration of heart and metabolic impact

Bridgebio, with FDA approval, faces Pfizer in ATTR

BioWorld

With the U.S. FDA approval of Attruby (acoramidis) for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), Bridgebio Pharma Inc. is taking on an industry...

Radiopharma Telix acquires FAP-targeting agents for bladder cancer

BioWorld

Radiopharmaceutical company Telix Pharmaceuticals Ltd. has inked a deal worth up to AU$264 million (US$171 million) to license and develop next-generation...

Upgrade your daily dose of biopharma and medtech news

Daiichi Sankyo wins approval in Japan for first oncolytic virus therapy treating malignant glioma